

Cases from the Community: Urologic Oncology Investigators Provide Perspectives on the Optimal Management of Urothelial Bladder Cancer (Webinar Video Proceedings)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following is targeted by erdafitinib?
 - a. FGFR
 - b. Nectin-4
 - c. Trop-2
 - d. HER3

2. The ongoing Phase III POTOMAC trial is evaluating the anti-PD-L1 antibody durvalumab in which of the following settings?
 - a. As monotherapy for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) unresponsive or refractory to BCG therapy
 - b. In combination with BCG for patients with high-risk, BCG-naïve NMIBC
 - c. As maintenance therapy after front-line chemotherapy for patients with metastatic urothelial bladder carcinoma (mUBC)
 - d. In combination with enfortumab vedotin for patients with mUBC

3. Which of the following Grade 3 or higher adverse events was most commonly reported with enfortumab vedotin in the EV-301 trial?
 - a. Diarrhea
 - b. Alopecia
 - c. Febrile neutropenia
 - d. Rash

4. What is the mechanism of action of TAR-200?
 - a. Antibody-drug conjugate
 - b. FGFR inhibitor
 - c. Anti-PD-1/PD-L1 antibody
 - d. Intravesicular gemcitabine

5. Which of the following any-grade adverse events was most commonly observed in the TROPHY-U-01 trial evaluating sacituzumab govitecan for patients with mUBC?
 - a. Febrile neutropenia
 - b. Diarrhea
 - c. Urinary tract infection
 - d. Dyschromia